The 1-Click DataLake’s insights are intended to aid trial design, feasibility assessments, and trial execution.

Positive data from EXPERTS-ALS could accelerate RT1999 towards a registration trial; RT1999 to be presented as a poster ...

“Our partnership with CRIO accelerates our strategy connecting site-level eSource and the Medidata Platform,” said Tom Doyle, chief technology officer, Medidata. “This will accelerate workflows for ...

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg ...

Povorcitinib 75 mg achieved high-threshold lesion clearance by week 12, including 100% draining-tunnel reduction in 12%–57% and total abscess clearance in 22%–62% of participants. Phase 3 data show ...

New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures The research assesses how protocol design ...

PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...

This article is part of our series on clinical data considerations. Read How to Prepare for Disclosure. For publicly traded biotech companies, disclosing clinical trial data can be an exciting ...

Research found just 4% of trials over the past decade allowed the inclusion of pregnant women.

Attention-deficit/hyperactivity disorder or ADHD translates in different ways across the population, unlike the ...

SHINKEI THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL FOR MR-101 AND COMPLETES PHASE 2 ...

Based on the clinical trial findings, Ipsen is withdrawing Tazverik across all indications, including both follicular lymphoma and epithelioid sarcoma, and is discontinuing all active tazemetostat ...